scispace - formally typeset
M

Michael T. Lotze

Researcher at University of Pittsburgh

Publications -  458
Citations -  47461

Michael T. Lotze is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 103, co-authored 448 publications receiving 42985 citations. Previous affiliations of Michael T. Lotze include University of Tokyo & GlaxoSmithKline.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

The Beclin 1 network regulates autophagy and apoptosis

Rui Kang, +3 more
- 11 Feb 2011 - 
TL;DR: New findings regarding the organization and function of the Beclin 1 network in cellular homeostasis are summarized, focusing on the cross-regulation between apoptosis and autophagy.
Journal ArticleDOI

The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

Allan Tsung, +10 more
- 04 Apr 2005 - 
TL;DR: It is demonstrated that HMGB1 is an early mediator of injury and inflammation in liver I/R and implicates TLR4 as one of the receptors that is involved in the process.
Journal ArticleDOI

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Laurence Zitvogel, +6 more
- 01 Jan 1996 - 
TL;DR: Using the immunogenic C3 (H-2b) tumor model in B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tumors and long-term survival in 100% of treated animals.